Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more
Nanjing Hicin Pharmaceutical Co Ltd (300584) - Total Liabilities
Latest total liabilities as of September 2025: CN¥410.14 Million CNY
Based on the latest financial reports, Nanjing Hicin Pharmaceutical Co Ltd (300584) has total liabilities worth CN¥410.14 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanjing Hicin Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nanjing Hicin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing Hicin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou Heshun Technology Co.LTD.
SHE:301237
|
China | CN¥496.73 Million |
|
MGP Ingredients Inc
NASDAQ:MGPI
|
USA | $519.07 Million |
|
engcon AB Cl B
ST:ENGCON-B
|
Sweden | Skr615.00 Million |
|
Chengdu Huasun Group Inc Ltd
SHE:000790
|
China | CN¥911.88 Million |
|
Shaanxi Kanghui Pharm Co Ltd
SHG:603139
|
China | CN¥1.14 Billion |
|
Orange Belgium SA
BR:OBEL
|
Belgium | €3.07 Billion |
|
Ningbo Haitian Precision Machinery Co Ltd
SHG:601882
|
China | CN¥2.29 Billion |
|
Joeone Co Ltd
SHG:601566
|
China | CN¥1.61 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Nanjing Hicin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing Hicin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing Hicin Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total liabilities of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥426.37 Million | +1.19% |
| 2023-12-31 | CN¥421.37 Million | +22.71% |
| 2022-12-31 | CN¥343.38 Million | -2.87% |
| 2021-12-31 | CN¥353.53 Million | +55.37% |
| 2020-12-31 | CN¥227.55 Million | +5.74% |
| 2019-12-31 | CN¥215.19 Million | +0.91% |
| 2018-12-31 | CN¥213.26 Million | +86.07% |
| 2017-12-31 | CN¥114.61 Million | +21.08% |
| 2016-12-31 | CN¥94.66 Million | +8.12% |
| 2015-12-31 | CN¥87.55 Million | -6.50% |
| 2014-12-31 | CN¥93.63 Million | +24.04% |
| 2013-12-31 | CN¥75.49 Million | +30.09% |
| 2012-12-31 | CN¥58.03 Million | -- |